Nuvectis Signs Ex-China License with Haisco for CFB Inhibitor and BRAF Inhibitor in Oncology and Complement Disease

Two Chinese-origin clinical assets are now moving into Western regulatory pipelines after Nuvectis Pharma secured exclusive ex-China rights to NXP100, a once-daily oral Complement Factor B inhibitor, and NXP200, a brain-penetrant paradox-breaker BRAF inhibitor, from Haisco Pharmaceutical Group. For CMC and regulatory teams, the transaction signals an immediate workload around bridging studies and FDA/EMA submission strategies for compounds with existing Chinese clinical packages.

NXP100 (HSK39297) carries the most advanced regulatory footprint. Two Marketing Authorization Applications are currently under review in China for Paroxysmal Nocturnal Hemoglobinuria, covering both treatment-naive patients and those who have failed a C5 inhibitor. A Phase 3 trial in IgA Nephropathy is ongoing, and a Phase 2 in Lupus Nephritis is active. Translating that dataset for Western submissions will require careful alignment with ICH E5 bridging requirements and FDA's expectations on ethnic sensitivity data.

NXP200 (HSK42360) is earlier in development, with a Phase 1b study ongoing in China. The compound targets BRAF V600X-mutated and Class II/III non-V600-mutated malignancies and has shown single-agent durable responses across CNS, colorectal, melanoma, non-small-cell lung cancer, and papillary thyroid tumors. The brain-penetrant profile adds a formulation complexity dimension that process development and analytical teams will need to address ahead of any IND filing in the US or Europe.

Haisco's track record is relevant context for due diligence teams assessing the quality of the incoming data packages. The Shenzhen-listed company holds approximately 50 marketed products and 70 research programs, and completed licensing transactions with both Eli Lilly and AbbVie in Q2 2026. Its envudeucitinib, a JAK inhibitor for plaque psoriasis, reached Phase 3 success before being licensed to Alumis, establishing a precedent for the quality of assets Haisco advances to out-licensing stage.

For QA and regulatory leads at Nuvectis, the near-term priority will be assessing whether existing GMP manufacturing records and analytical method validation packages from Haisco's Chinese facilities meet 21 CFR Part 211 and EU GMP standards, or whether technology transfer and revalidation will be required before Western clinical supply can be established. The depth and format of Haisco's process validation documentation will determine how quickly NXP100 can enter US or European clinical trials.

The pace at which Nuvectis can convert NXP100's Chinese MAA dataset into an FDA-aligned submission package will set the timeline for any IND or NDA filing and define the regulatory risk profile of this transaction.

Source: GlobeNewswire via Nuvectis Pharma press release, 22 June 2026. Nuvectis held an investor conference call at 8:30 AM ET on the same date.